<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782546</url>
  </required_header>
  <id_info>
    <org_study_id>201610088</org_study_id>
    <secondary_id>1P50CA171963-01A1</secondary_id>
    <secondary_id>2P50CA171963-06</secondary_id>
    <nct_id>NCT02782546</nct_id>
  </id_info>
  <brief_title>Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation</brief_title>
  <official_title>A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The V Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia&#xD;
      free survival to 30% from &lt;10% expected with the use of reduced intensity haplo-HCT in this&#xD;
      extremely high-risk patient cohort (based on the institutional experience using&#xD;
      non-myeloablative / reduced intensity conditioning in a similar patient cohort).&#xD;
&#xD;
      A formal safety evaluation will be done after every 6th patient enrolled and the trial will&#xD;
      be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (&gt;60% any&#xD;
      grades or &gt;30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leukemia free survival rate (LFS)</measure>
    <time_frame>1 year post transplantation</time_frame>
    <description>-LFS is defined as the time from achievement of CR to the time of relapse, death in remission, or last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival rate (LFS)</measure>
    <time_frame>3 months post transplantation</time_frame>
    <description>-LFS is defined as the time from achievement of CR to the time of relapse, death in remission, or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival (OS)</measure>
    <time_frame>1 year post transplantation</time_frame>
    <description>-OS is defined as the time from the date of Day 0 until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse in patients who are found to be CR (complete remission)</measure>
    <time_frame>Day 28 post transplantation</time_frame>
    <description>-CR: Morphologically leukemia free state (i.e. bone marrow with &lt;5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care reduced conditioning regimen on Day -1&#xD;
Graft cell infusion on Day 0&#xD;
Post-transplant cyclophosphamide on Days +3 and +4&#xD;
GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD&#xD;
G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines&#xD;
The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.&#xD;
ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.&#xD;
Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.&#xD;
On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Graft cell infusion</intervention_name>
    <description>-Day 0</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>-GVHD prophylaxis</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>-GVHD prophylaxis</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>-Continue until neutrophil engraftment as per institutional guidelines</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Granulocyte-colony stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CIML NK cell infusion</intervention_name>
    <description>-Day +7</description>
    <arm_group_label>Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>-Start approximately 4 hours after CIML NK cell infusion</description>
    <arm_group_label>Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>-Day +6</description>
    <arm_group_label>Donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:&#xD;
&#xD;
          -  Refractory AML without complete remission (CR) after 2 or more cycles of induction&#xD;
             therapy (primary induction failure), or AML relapsed after obtaining a CR and failed&#xD;
             one or more cycles of re-induction therapy. Standard dose 10-day decitabine (20 mg/m2&#xD;
             daily IV x 10 days) or 7-day azacitidine (75-100 mg/m2 daily SC/IV x 7 days) will be&#xD;
             considered as one cycle of induction therapy.&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Available HLA-haploidentical donor that meets the criteria in the protocol&#xD;
&#xD;
          -  Patients with known CNS involvement with AML are eligible provided that they have been&#xD;
             treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS&#xD;
             therapy (chemotherapy or radiation) should continue as medically indicated during the&#xD;
             study treatment.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 60 %&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               -  Total bilirubin &lt; 2 mg/dl&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt; 3.0 x IULN&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR creatinine clearance &gt; 60&#xD;
                  mL/min/1.73 m2 by Cockcroft-Gault Formula&#xD;
&#xD;
               -  Oxygen saturation ≥90% on room air and adjusted DLCO of at least 40%&#xD;
&#xD;
               -  Ejection fraction ≥40%&#xD;
&#xD;
          -  Able to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of&#xD;
             other systemic steroids are allowed) and any other immune suppressive medications&#xD;
             beginning on Day -3&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test within 28 days&#xD;
             prior to study registration. Female and male patients (along with their female&#xD;
             partners) must agree to use two forms of acceptable contraception, including one&#xD;
             barrier method, during participation in the study and throughout the DLT evaluation&#xD;
             period.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  Relapsed after allogeneic transplantation.&#xD;
&#xD;
          -  Circulating blast count &gt;30,000/uL by morphology or flow cytometry (cyto-reductive&#xD;
             therapies including leukapheresis or hydroxyurea are allowed).&#xD;
&#xD;
          -  Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.&#xD;
&#xD;
          -  Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of&#xD;
             &gt;5000 as assessed by the single antigen bead assay, &lt; 6 weeks prior to starting&#xD;
             transplant conditioning&#xD;
&#xD;
          -  Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of&#xD;
             acute ischemia or active conduction system abnormalities.&#xD;
&#xD;
          -  New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that&#xD;
             have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be&#xD;
             stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven&#xD;
             fungal infections)&#xD;
&#xD;
          -  Known hypersensitivity to one or more of the study agents&#xD;
&#xD;
          -  Received any investigational drugs within the 14 days prior to the first day of&#xD;
             transplant conditioning&#xD;
&#xD;
          -  Pregnant and/or breastfeeding&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  Related donor (sibling, offspring, or offspring of sibling)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  HLA-haploidentical donor/recipient match by at least Class I serologic typing at the&#xD;
             A&amp;B locus.&#xD;
&#xD;
          -  In general good health, and medically able to tolerate leukapheresis required for&#xD;
             harvesting the NK cells for this study.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Positive for hepatitis, HTLV, or HIV infection&#xD;
&#xD;
          -  Pregnant and/or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Cashen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Cashen, M.D.</last_name>
    <phone>(314) 454-8323</phone>
    <email>acashen@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Cashen, M.D.</last_name>
      <phone>314-454-8323</phone>
      <email>acashen@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Westervelt, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Uy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Vij, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meagan Jacoby, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Ghobadi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Schroeder, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Stockerl-Goldstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

